Insider Selling: Nurix Therapeutics, Inc. (NASDAQ:NRIX) General Counsel Sells 1,200 Shares of Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) General Counsel Christine Ring sold 1,200 shares of Nurix Therapeutics stock in a transaction dated Tuesday, July 20th. The shares were sold at an average price of $27.00, for a total value of $32,400.00. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Christine Ring also recently made the following trade(s):

  • On Thursday, June 10th, Christine Ring sold 1,200 shares of Nurix Therapeutics stock. The stock was sold at an average price of $29.40, for a total transaction of $35,280.00.
  • On Monday, May 10th, Christine Ring sold 1,200 shares of Nurix Therapeutics stock. The stock was sold at an average price of $27.00, for a total transaction of $32,400.00.

Nurix Therapeutics stock opened at $30.11 on Thursday. The company has a market capitalization of $1.34 billion and a PE ratio of -12.92. Nurix Therapeutics, Inc. has a fifty-two week low of $15.21 and a fifty-two week high of $52.38. The stock has a fifty day moving average price of $27.29.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings results on Monday, July 12th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.54) by ($0.06). Nurix Therapeutics had a negative return on equity of 28.14% and a negative net margin of 389.44%. On average, research analysts expect that Nurix Therapeutics, Inc. will post -2.49 earnings per share for the current fiscal year.

A number of large investors have recently made changes to their positions in the stock. Squarepoint Ops LLC purchased a new position in Nurix Therapeutics in the first quarter worth $491,000. Baker BROS. Advisors LP grew its position in Nurix Therapeutics by 37.2% in the first quarter. Baker BROS. Advisors LP now owns 2,454,082 shares of the company’s stock worth $76,297,000 after acquiring an additional 665,161 shares in the last quarter. Millennium Management LLC grew its position in Nurix Therapeutics by 111.9% in the first quarter. Millennium Management LLC now owns 239,935 shares of the company’s stock worth $7,460,000 after acquiring an additional 126,731 shares in the last quarter. Voloridge Investment Management LLC purchased a new position in Nurix Therapeutics in the first quarter worth $1,970,000. Finally, D. E. Shaw & Co. Inc. purchased a new position in Nurix Therapeutics in the first quarter worth $1,281,000. Institutional investors own 92.60% of the company’s stock.

A number of equities research analysts recently commented on the stock. Royal Bank of Canada assumed coverage on shares of Nurix Therapeutics in a report on Friday, April 30th. They issued an “outperform” rating and a $42.00 price target on the stock. Zacks Investment Research raised shares of Nurix Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, June 16th. Needham & Company LLC initiated coverage on shares of Nurix Therapeutics in a report on Thursday, July 15th. They set a “buy” rating and a $48.00 target price on the stock. Finally, Berenberg Bank initiated coverage on shares of Nurix Therapeutics in a report on Wednesday, April 14th. They set a “buy” rating on the stock. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $46.67.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader with immunomodulatory drug (IMiD) activity for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader without IMiD activity for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

Read More: Backdoor Roth IRA

Insider Buying and Selling by Quarter for Nurix Therapeutics (NASDAQ:NRIX)

Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.